A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients
| Autor: | Luca Triggiani, Sara Pedretti, Rebecca Pedersini, L. Pegurri, Edda Simoncini, Michela Buglione, Andrea Emanuele Guerini, Stefano Maria Magrini, Gianluca Costantino, Filippo Alongi, G. Peretto, Lucia Vassalli, Emiliano Salah, Vanessa Figlia, Marta Maddalo, Nadia Pasinetti |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Neutropenia Palliative Radiation Therapy Cancer therapy Pyridines medicine.medical_treatment lcsh:Medicine Aminopyridines Breast Neoplasms Palbociclib Single Center Piperazines Article 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine Outcome Assessment Health Care Medicine Humans Molecular Targeted Therapy Neoplasm Metastasis lcsh:Science Protein Kinase Inhibitors Retrospective Studies Multidisciplinary Radiotherapy business.industry lcsh:R Cyclin-Dependent Kinase 4 Cyclin-Dependent Kinase 6 Ileitis medicine.disease Metastatic breast cancer Combined Modality Therapy Radiation therapy 030104 developmental biology Purines Concomitant lcsh:Q Female business 030217 neurology & neurosurgery |
| Zdroj: | Scientific Reports Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020) |
| Popis: | Cyclin dependent kinases 4/6 (CDK4/6) inhibitors gained an essential role in the treatment of metastatic breast cancer. Nevertheless, data regarding their use in combination with radiotherapy are still scarce. We performed a retrospective preliminary analysis of breast cancer patients treated at our Center with palliative radiation therapy and concurrent CDK4/6 inhibitors. Toxicities were measured according to CTCAE 4.0, local response according to RECIST 1.1 or PERCIST 1.0 and pain control using verbal numeric scale. 18 patients (32 treated sites) were identified; 50% received palbociclib, 33.3% ribociclib and 16.7% abemacliclib. Acute non-hematologic toxicity was fair, with the only exception of a patient who developed G3 ileitis. During 3 months following RT, 61.1% of patients developed G 3–4 neutropenia; nevertheless no patient required permanent suspension of treatment. Pain control was complete in 88.2% of patients three months after radiotherapy; 94.4% of patients achieved and maintained local control of disease. Radiotherapy concomitant to CDK4/6 inhibitors is feasible and characterized by a fair toxicity profile, with isolated episodes of high-grade reversible intestinal toxicity. Rate of G 3–4 neutropenia was comparable with that measured for CDK4/6 inhibitors alone. Promising results were reported in terms of pain relief and local control of disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|